FRA:2EM - Deutsche Boerse Ag - GB00BN7ZCY67 - Common Stock - Currency: EUR
FRA:2EM (3/31/2023, 7:00:00 PM)
11
-0.42 (-3.68%)
The current stock price of 2EM.DE is 11 EUR. In the past month the price decreased by -24.66%. In the past year, price decreased by -36.96%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TN8.DE | THERMO FISHER SCIENTIFIC INC | 17.93 | 128.71B | ||
DAP.DE | DANAHER CORP | 26.04 | 120.59B | ||
LO3.DE | LONZA GROUP AG-REG | 37.16 | 42.79B | ||
56S1.DE | SARTORIUS STEDIM BIOTECH | 51.97 | 19.22B | ||
DIM.PA | SARTORIUS STEDIM BIOTECH | 51.75 | 19.14B | ||
SRT3.DE | SARTORIUS AG-VORZUG | 49.4 | 15.80B | ||
SRT.DE | SARTORIUS AG | 39.86 | 12.74B | ||
ILU.DE | ILLUMINA INC | 27.1 | 12.40B | ||
ESF0.DE | EUROFINS SCIENTIFIC | 33.63 | 11.03B | ||
ERF.PA | EUROFINS SCIENTIFIC | 32.94 | 10.80B | ||
QIA.DE | QIAGEN N.V. | 20.41 | 8.79B | ||
1SXP.DE | SCHOTT PHARMA AG& CO KGAA | 28.27 | 4.17B |
Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. The company is headquartered in Guildford, Surrey and currently employs 1,255 full-time employees. The company went IPO on 2014-07-15. The firm operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). Its CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. Its PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The firm serves over 100 countries. The company operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Companies subsidiaries include PrimeVigilance Inc., PrimeVigilance USA Inc., PrimeVigilance s.r.o., PharmInvent regulatory s.r.o., PrimeVigilance Japan K.K., Haemostatix Limited and Sound Opinion Limited.
ERGOMED PLC
1 Occam Court, Occam Road
Guildford SURREY GB
Employees: 1255
Phone: 441483503205.0
The current stock price of 2EM.DE is 11 EUR. The price decreased by -3.68% in the last trading session.
The exchange symbol of ERGOMED PLC is 2EM and it is listed on the Deutsche Boerse Ag exchange.
2EM.DE stock is listed on the Deutsche Boerse Ag exchange.
12 analysts have analysed 2EM.DE and the average price target is 16.93 EUR. This implies a price increase of 53.9% is expected in the next year compared to the current price of 11. Check the ERGOMED PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ERGOMED PLC (2EM.DE) has a market capitalization of 558.54M EUR. This makes 2EM.DE a Small Cap stock.
ERGOMED PLC (2EM.DE) currently has 1255 employees.
ERGOMED PLC (2EM.DE) has a support level at 10.99 and a resistance level at 11.43. Check the full technical report for a detailed analysis of 2EM.DE support and resistance levels.
The Revenue of ERGOMED PLC (2EM.DE) is expected to grow by 12.58% in the next year. Check the estimates tab for more information on the 2EM.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
2EM.DE does not pay a dividend.
The PE ratio for ERGOMED PLC (2EM.DE) is 33.33. This is based on the reported non-GAAP earnings per share of 0.33 and the current share price of 11 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 2EM.DE.
ChartMill assigns a fundamental rating of 5 / 10 to 2EM.DE. While 2EM.DE has a great health rating, its profitability is only average at the moment.
Over the last trailing twelve months 2EM.DE reported a non-GAAP Earnings per Share(EPS) of 0.33. The EPS increased by 16.6% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 10.31% | ||
ROA | 11.58% | ||
ROE | 17.68% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 85% to 2EM.DE. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 15.11% and a revenue growth 12.58% for 2EM.DE